![Focus research 2022 GENIM team](https://www.crct-inserm.fr/wp-content/uploads/2021/11/Team-13-bandeau-2-1080x554.jpg)
![Focus research 2022 GENIM team](https://www.crct-inserm.fr/wp-content/uploads/2021/11/Team-13-bandeau-2-1080x554.jpg)
![Cancer: a key mechanism for improving immunotherapies identified by a Toulouse team](https://www.crct-inserm.fr/wp-content/uploads/2023/06/immunotherapie-1000x675.jpg)
Cancer: a key mechanism for improving immunotherapies identified by a Toulouse team
Cancer: a key mechanism for improving immunotherapies identified by a Toulouse team Cancer, Immunology, Immunotherapy, Lymphocytes, Depletion. Ludovic Martinet Team GENIM Genomic and immunology of myeloma A team from the Centre de Recherches en Cancérologie de...![Heterogeneity in long-term outcomes for R-ISS stage II in newly diagnosed multiple myeloma patients](https://www.crct-inserm.fr/wp-content/uploads/2022/10/myeloma-details.png)
Heterogeneity in long-term outcomes for R-ISS stage II in newly diagnosed multiple myeloma patients
Heterogeneity in long-term outcomes for R-ISS stage II in newly diagnosed multiple myeloma patients Multiple myeloma, Cytogenetics, Prognosis Anaïs Schavgoulidze – Team GENIM – Genomic and Immunology of myeloma Multiple myeloma (MM) is characterized by...![More news](https://www.crct-inserm.fr/wp-content/uploads/2022/01/genetique-tumorale-1000x675.jpg)
More news
Very soon more news from this team to follow….